Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Oxaliplatin in Second-line Metastatic Pancreatic Cancer
NCT00690300Phase 2Unknown
- Sponsor
- Ulm University
- Start
- Jan 2008
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Ulm University. Status: unknown.
02
Drugs
docetaxeloxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00690300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00690300.